Safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis in Brazil.
Carlos Alberto de Castro PereiraJosé Antonio Baddini-MartinezAndré Luis Pereira de AlbuquerqueSérgio Fernandes de Oliveira JezlerAdalberto Sperb RuninRogerio Lopes Rufino AlvesGilmar Alves ZonzinManuel QuaresmaMatthias TrampischMarcelo Fouad RabahiPublished in: Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia (2019)
In the Brazilian EAP, nintedanib had an acceptable safety and tolerability profile in patients with IPF, consistent with data from clinical trials.